The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
COST Action CA15105 – Breakthrough networking and sharing responsibilities to cope with the Medicines Shortages challenge
Room:
Salle de Presse
Facilitator:
Helena Jenzer
Speakers:
- Elfi De Weerdt
- Jane Nicholson
- Tomasz Bochenek
- João Luís de Miranda
- David G. Schwartz
- Isabelle Huys
- Helena Jenzer
Abstract:
ACPE UAN: 0475-0000-17-026-L04-P. A knowledge based activity.
Abstract
The problems created by supply shortages of medicines have been widely reported by healthcare professionals and patients over recent years, and acknowledged by the European Medicines Agency and European Commission. The cited causes are multifaceted ranging from production disruptions, natural disasters, discontinuations, difficulties created by various restrictive and disincentive legal, trade and pricing frameworks, unfavorable decision making in medicines production and trade, insufficient stocks, as well as conflicts of interest of stakeholders. COST Action CA15105 – European Medicines Shortages Research Network – addressing supply problems to patients (acronym: Medicines Shortages) is the platform which joins together all stakeholders and particular interests along the supply chain. This chain can be parted into processes such as production of active ingredients, manufacturing, wholesaling, clinical need, and measures of poor clinical, financial and quality of life outcomes arising from shortages.
The Action aims to respond to clinical, financial and quality of life interests, to achieve analytical clarity on disruption causes, to simulate decision making, and to reflect on best coping practices. Activities of the COST framework in the upcoming three years will make a significant contribution to strategic thinking about how to respond to product shortage problems by systematically analyzing the situation from key player perspectives. This includes round table negotiations with the stakeholders. It is the declared aim of the project to bring together all the primary stakeholders in the medicines supply chain process to find by a bottom-up approach an agreement on the paths towards resolution. The final objective is to stimulate constructive agreement between all participating stakeholders and to reveal any restrictive legal and economic frameworks, erroneous incentives in the supply chain, conflicts of interest, and problematic cost-benefit ratios that induce or exacerbate shortages. Presenters from all 5 COST Action Working Groups will outline current research projects and latest results.
Learning objectives
Congress delegates will be able to:
• locate current medicines shortages research projects performed by academy and practice;
• transfer and apply new information, methods and approaches to their own daily work;
• share their own research and activities with COST Action CA15105 in the remaining running time of the Action.
Keywords: medicines shortages, promising approaches for improvement, intermediate results from the Action
* No conflict of interest has been declared.